Literature DB >> 29057313

A lipid off-switch for mTORC1.

Alexander Wallroth1, Volker Haucke1.   

Abstract

Mammalian target of rapamycin complex 1 (mTORC1) is a central regulator of metabolism, cell growth and survival. Our finding that local phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2] synthesis at late endosomes/ lysosomes by class II PI3Kβ (PI3KC2β) represses mTORC1 identifies PI3KC2β as a pharmacological target for the treatment of diabetes and cancer.

Entities:  

Keywords:  cancer; class II PI 3-kinase; diabetes; late endosomes/ lysosomes; mTORC1; nutrient signaling; phosphoinositides

Year:  2017        PMID： 29057313      PMCID： PMC5644471          DOI： 10.1080/23723556.2017.1356899

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.

Authors:  Dan Ehninger
Journal:  Neuropharmacology       Date:  2012-05-22       Impact factor: 5.250

2.  Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.

Authors:  Jessica J Howell; Kristina Hellberg; Marc Turner; George Talbott; Matthew J Kolar; Debbie S Ross; Gerta Hoxhaj; Alan Saghatelian; Reuben J Shaw; Brendan D Manning
Journal:  Cell Metab       Date:  2017-01-12       Impact factor: 27.287

Review 3.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

4.  mTOR Signaling in Growth, Metabolism, and Disease.

Authors:  Robert A Saxton; David M Sabatini
Journal:  Cell       Date:  2017-04-06       Impact factor: 41.582

5.  PI(3,4,5)P3 Engagement Restricts Akt Activity to Cellular Membranes.

Authors:  Michael Ebner; Iva Lučić; Thomas A Leonard; Ivan Yudushkin
Journal:  Mol Cell       Date:  2017-02-02       Impact factor: 17.970

6.  mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate.

Authors:  Andrea L Marat; Alexander Wallroth; Wen-Ting Lo; Rainer Müller; Giuseppe Danilo Norata; Marco Falasca; Carsten Schultz; Volker Haucke
Journal:  Science       Date:  2017-06-02       Impact factor: 47.728

7.  Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.

Authors:  Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Michiko Sugiyama; Takashi Uchiyama; Kaori Suzuki; Yuichi Nozaki; Kyoko Yoneda; Koji Fujita; Masato Yoneda; Masahiko Inamori; Akiko Tomatsu; Takeshi Chihara; Kan Shimpo; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Mol Carcinog       Date:  2010-07       Impact factor: 4.784

8.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.

Authors:  Yasemin Sancak; Carson C Thoreen; Timothy R Peterson; Robert A Lindquist; Seong A Kang; Eric Spooner; Steven A Carr; David M Sabatini
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

9.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

10.  AMPK phosphorylation of raptor mediates a metabolic checkpoint.

Authors:  Dana M Gwinn; David B Shackelford; Daniel F Egan; Maria M Mihaylova; Annabelle Mery; Debbie S Vasquez; Benjamin E Turk; Reuben J Shaw
Journal:  Mol Cell       Date:  2008-04-25       Impact factor: 17.970
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.